What is the share price of Fredun Pharmaceuticals Ltd (FREDUN) today?
The share price of FREDUN as on 5th December 2025 is ₹1874.10. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Fredun Pharmaceuticals Ltd (FREDUN) share?
The past returns of Fredun Pharmaceuticals Ltd (FREDUN) share are- Past 1 week: 2.97%
- Past 1 month: 23.44%
- Past 3 months: 44.73%
- Past 6 months: 156.52%
- Past 1 year: 140.27%
- Past 3 years: 38.71%
- Past 5 years: 553.00%
What are the peers or stocks similar to Fredun Pharmaceuticals Ltd (FREDUN)?
The peers or stocks similar to Fredun Pharmaceuticals Ltd (FREDUN) include:What is the dividend yield % of Fredun Pharmaceuticals Ltd (FREDUN) share?
The current dividend yield of Fredun Pharmaceuticals Ltd (FREDUN) is 0.04.What is the market cap of Fredun Pharmaceuticals Ltd (FREDUN) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Fredun Pharmaceuticals Ltd (FREDUN) is ₹884.89 Cr as of 5th December 2025.What is the 52 week high and low of Fredun Pharmaceuticals Ltd (FREDUN) share?
The 52-week high of Fredun Pharmaceuticals Ltd (FREDUN) is ₹1999 and the 52-week low is ₹635.What is the PE and PB ratio of Fredun Pharmaceuticals Ltd (FREDUN) stock?
The P/E (price-to-earnings) ratio of Fredun Pharmaceuticals Ltd (FREDUN) is 44.83. The P/B (price-to-book) ratio is 7.28.Which sector does Fredun Pharmaceuticals Ltd (FREDUN) belong to?
Fredun Pharmaceuticals Ltd (FREDUN) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Fredun Pharmaceuticals Ltd (FREDUN) shares?
You can directly buy Fredun Pharmaceuticals Ltd (FREDUN) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Fredun Pharmaceuticals Ltd
FREDUN Share Price
1,874.102.26% (-43.35)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
FREDUN Stock Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
FREDUN Performance & Key Metrics
FREDUN Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 24.61 | 7.28 | 0.04% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.87 | 5.82 | 0.59% |
FREDUN Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
FREDUN Company Profile
Fredun Pharmaceuticals Ltd. is a pharmaceutical company engaged in the manufacturing and sale of pharmaceutical formulations. The Company’s products include I V fluids, disposable syringes, infusion sets, surgical gloves and cottons etc.
SUNPHARMA
PE Ratio
39.63
39.63
1Y Return
0.45%
0.45%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.04
67.04
1Y Return
12.63%
12.63%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.51%
1.51%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.77
18.77
1Y Return
2.85%
2.85%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.21
29.21
1Y Return
1.24%
1.24%
Buy Reco %
72.22
72.22
FREDUN Sentiment Analysis
FREDUN Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
FREDUN Stock Summary · November 2025
The company is experiencing steady growth, driven by a strategic shift towards becoming a diversified healthcare provider, particularly in the burgeoning pet care market. With plans to enhance manufacturing capacity and optimize operational efficiency, management is focused on innovation and expanding its product range, including nutraceuticals and ethical pet nutrition. The recent acquisition of a pet tech platform aims to create a comprehensive ecosystem for pet wellness, addressing market gaps and fostering brand trust among consumers. As the company navigates international expansion while solidifying its domestic base, it remains committed to sustainable growth through talent acquisition and a robust e-commerce platform that supports small manufacturers. Overall, the outlook is cautiously optimistic, with strong demand for new products and a disciplined approach to long-term vision.
FREDUN Stock Growth Drivers
FREDUN Stock Growth Drivers
7Strong Financial Performance
Fredun Pharmaceuticals Limited has reported significant financial growth, with Q2 FY '26 total income reaching
Expansion and Diversification
The company has successfully transformed into a diversified healthcare entity with a strong presence in
FREDUN Stock Challenges
FREDUN Stock Challenges
0
Hmm, looks like there are nochallenges
FREDUN Forecast
FREDUN Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
FREDUN
FREDUN
Income
Balance Sheet
Cash Flow
Annual Normal View
FREDUN Income Statement
FREDUN Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 58.61 | 59.71 | 97.40 | 113.29 | 135.29 | 226.09 | 276.50 | 349.08 | 456.27 | 721.42 | ||||||||||
Raw Materials | 34.20 | 42.98 | 65.96 | 86.12 | 100.60 | 176.45 | 245.57 | 282.42 | 401.36 | 627.18 | ||||||||||
| Power & Fuel Cost | 1.64 | 1.65 | 3.10 | 3.21 | 3.32 | 3.68 | 3.17 | 4.03 | ||||||||||||
| Employee Cost | 4.92 | 5.19 | 8.04 | 8.95 | 8.66 | 10.66 | 11.54 | 12.50 | ||||||||||||
| Selling & Administrative Expenses | 6.57 | 5.66 | 9.83 | 6.43 | 7.80 | 12.76 | 14.55 | 20.77 | ||||||||||||
| Operating & Other expenses | 6.04 | -1.64 | -0.14 | -0.27 | 5.33 | 7.04 | -27.93 | -9.55 | ||||||||||||
EBITDA | 5.24 | 5.87 | 10.61 | 8.85 | 9.58 | 15.50 | 29.60 | 38.91 | 54.91 | 94.24 | ||||||||||
| Depreciation/Amortization | 1.14 | 1.29 | 1.33 | 1.88 | 2.00 | 2.16 | 2.81 | 3.80 | 5.04 | 8.35 | ||||||||||
| PBIT | 4.10 | 4.58 | 9.28 | 6.97 | 7.58 | 13.34 | 26.79 | 35.11 | 49.87 | 85.89 | ||||||||||
| Interest & Other Items | 1.87 | 1.94 | 3.13 | 4.48 | 4.37 | 4.74 | 9.28 | 13.65 | 22.38 | 36.64 | ||||||||||
| PBT | 2.23 | 2.64 | 6.15 | 2.49 | 3.21 | 8.60 | 17.51 | 21.46 | 27.49 | 49.25 | ||||||||||
| Taxes & Other Items | 0.80 | 0.89 | 1.70 | 0.59 | 1.20 | 2.26 | 6.70 | 5.83 | 7.75 | 13.29 | ||||||||||
| Net Income | 1.43 | 1.75 | 4.45 | 1.90 | 2.01 | 6.34 | 10.81 | 15.63 | 19.74 | 35.96 | ||||||||||
| EPS | 5.97 | 6.01 | 12.00 | 4.76 | 5.04 | 15.06 | 24.12 | 33.86 | 44.83 | 76.52 | ||||||||||
| DPS | 0.60 | 0.60 | 0.65 | 0.66 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | ||||||||||
| Payout ratio | 0.10 | 0.10 | 0.05 | 0.14 | 0.14 | 0.05 | 0.03 | 0.02 | 0.02 | 0.01 |
FREDUN Company Updates
FREDUN Stock Peers
FREDUN Past Performance & Peer Comparison
FREDUN Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Fredun Pharmaceuticals Ltd | 44.83 | 7.28 | 0.04% |
| Sun Pharmaceutical Industries Ltd | 39.63 | 5.98 | 0.89% |
| Torrent Pharmaceuticals Ltd | 67.04 | 16.88 | 0.85% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
FREDUN Stock Price Comparison
Compare FREDUN with any stock or ETFCompare FREDUN with any stock or ETF
FREDUN
FREDUN Holdings
FREDUN Shareholdings
FREDUN Promoter Holdings Trend
FREDUN Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
FREDUN Institutional Holdings Trend
FREDUN Institutional Holdings Trend
Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has increased by 2.14%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
FREDUN Shareholding Pattern
FREDUN Shareholding Pattern
FREDUN Shareholding History
FREDUN Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing FREDUN stock
smallcases containing FREDUN stock
Looks like this stock is not in any smallcase yet.
FREDUN Events
FREDUN Events
FREDUN Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
FREDUN has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.04%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹0.37 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
FREDUN Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
FREDUN has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.04%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹0.37 every year
FREDUN Upcoming Dividends
FREDUN Upcoming Dividends
No upcoming dividends are available
FREDUN Past Dividends
FREDUN Past Dividends
Cash Dividend
Ex DateEx DateSep 23, 2025
Final
Final | Div/Share: ₹0.70
Dividend/Share
₹0.70
Ex DateEx Date
Sep 23, 2025
Cash Dividend
Ex DateEx DateSep 23, 2024
Final
Final | Div/Share: ₹0.70
Dividend/Share
₹0.70
Ex DateEx Date
Sep 23, 2024
Cash Dividend
Ex DateEx DateSep 22, 2023
Final
Final | Div/Share: ₹0.70
Dividend/Share
₹0.70
Ex DateEx Date
Sep 22, 2023
Cash Dividend
Ex DateEx DateSep 16, 2021
Final
Final | Div/Share: ₹0.70
Dividend/Share
₹0.70
Ex DateEx Date
Sep 16, 2021
Cash Dividend
Ex DateEx DateSep 16, 2019
Final
Final | Div/Share: ₹0.65
Dividend/Share
₹0.65
Ex DateEx Date
Sep 16, 2019
FREDUN Stock News & Opinions
FREDUN Stock News & Opinions
Articles & Videos
Earnings
Fredun Pharmaceuticals standalone net profit rises 127.87% in the September 2025 quarter
Net profit of Fredun Pharmaceuticals rose 127.87% to Rs 9.73 crore in the quarter ended September 2025 as against Rs 4.27 crore during the previous quarter ended September 2024. Sales rose 34.33% to Rs 143.59 crore in the quarter ended September 2025 as against Rs 106.89 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales143.59106.89 34 OPM %15.5513.04 - PBDT14.608.63 69 PBT13.007.57 72 NP9.734.27 128 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Fredun Pharmaceuticals to announce Quarterly Result
Fredun Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 8 November 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Fredun Pharma gains after launching new product
The product, launched under Fredun's Freossi brand, is free from root vegetables, meat, and animal-derived ingredients, in line with Jain dietary principles. It is designed to support pet immunity, digestion, bone health, and energy. Snacky Jain will be initially available in six cities through veterinary clinics, online platforms, and retail partners, with expansion planned for Ahmedabad, Pune, Bengaluru, and Delhi. The product is manufactured at the company's WHO-GMP-certified Palghar facility. Fredun said the launch strengthens its position in India's pet healthcare market, estimated at Rs 10,000 crore and growing at over 22% annually. Fredun Pharmaceuticals, a healthcare and pharmaceuticals company offer a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products along with animal healthcare products. The company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America. On a standalone basis, Fredun Pharmaceuticals' net profit rose 63.92% to Rs 6.77 crore while net sales rose 53.99% to Rs 119.40 crore in Q1 June 2025 over Q1 June 2024. Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Fredun Pharmaceuticals launches 'Snacky Jain' for pets
Fredun Pharmaceuticals announced the launch of 'Snacky Jain' ' a true first of its kind, and India's first Jain functional food product specifically for pets. Snacky Jain, developed under the flagship Freossi brand, is a truly pioneering step in pet nutrition, establishing a new standard for ethical, inclusive feeding. The product is the first of its kind to be thoughtfully crafted to align with Jain dietary principles, being completely free from root vegetables, meat, and all animal-derived ingredients. Critically, it still delivers essential nutrients to support superior immunity, digestion, bone health, and energy in pets. This innovation reinforces Fredun's commitment to creating a 360' pet wellness ecosystem encompassing nutrition, grooming, diagnostics, and preventive care. Developed through in-house R&D, Snacky Jain combines natural, plant-based ingredients with functional health benefits, ensuring both taste and wellness for companion animals. Snacky Jain will be initially introduced across six cities, through veterinary clinics, online marketplaces, and Fredun's dedicated retail partners, with phased expansion planned for key pet care markets including Ahmedabad, Pune, Bengaluru, and Delhi. The product is manufactured at Fredun's WHO-GMP-certified Palghar facility, ensuring international standards of quality and safety. Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Fredun Pharmaceuticals to hold EGM
Fredun Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 22 October 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Fredun Pharmaceuticals announces board meeting date
Fredun Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 25 September 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Fredun Pharmaceuticals to hold AGM
Fredun Pharmaceuticals announced that the Annual General Meeting(AGM) of the company will be held on 30 September 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Fredun Pharmaceuticals standalone net profit rises 63.92% in the June 2025 quarter
Net profit of Fredun Pharmaceuticals rose 63.92% to Rs 6.77 crore in the quarter ended June 2025 as against Rs 4.13 crore during the previous quarter ended June 2024. Sales rose 53.99% to Rs 119.40 crore in the quarter ended June 2025 as against Rs 77.54 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales119.4077.54 54 OPM %14.2313.52 - PBDT10.466.57 59 PBT9.045.52 64 NP6.774.13 64 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Fredun Pharmaceuticals to convene board meeting
Fredun Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 30 July 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Fredun Pharmaceuticals standalone net profit rises 39.72% in the March 2025 quarter
Net profit of Fredun Pharmaceuticals rose 39.72% to Rs 7.07 crore in the quarter ended March 2025 as against Rs 5.06 crore during the previous quarter ended March 2024. Sales rose 41.15% to Rs 165.44 crore in the quarter ended March 2025 as against Rs 117.21 crore during the previous quarter ended March 2024. For the full year,net profit rose 33.23% to Rs 20.81 crore in the year ended March 2025 as against Rs 15.62 crore during the previous year ended March 2024. Sales rose 30.33% to Rs 451.71 crore in the year ended March 2025 as against Rs 346.58 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales165.44117.21 41 451.71346.58 30 OPM %10.549.53 -12.2011.22 - PBDT9.296.80 37 32.7225.25 30 PBT8.045.84 38 28.2721.45 32 NP7.075.06 40 20.8115.62 33 Powered by Capital Market - Live
5 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 32.13%, vs industry avg of 10.04%
Over the last 5 years, market share increased from 0.05% to 0.11%
Over the last 5 years, net income has grown at a yearly rate of 59.71%, vs industry avg of 20.02%